APO RESEARCH · REPORT
Antibody Therapeutics and Blood Antibody Therapeutics
Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.
Product & engineering
Understand the product.
Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.
Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.
Selected research
Industry Growth & Trends
Global Antibody Therapeutics and Blood Antibody Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.
Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.
According to APO Research, the global Antibody Therapeutics and Blood Antibody Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Read the full market overview
Report Scope
This report provides a structured, data-driven view of the global Antibody Therapeutics and Blood Antibody Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Antibody Therapeutics and Blood Antibody Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antibody Therapeutics and Blood Antibody Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antibody Therapeutics and Blood Antibody Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Antibody Therapeutics and Blood Antibody Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Antibody Therapeutics and Blood Antibody Therapeutics Market by Company
Roche
Abbvie
Johnson & Johnson
Bristol-Myers Squibb
Novartis
Merck
Alexion Pharmaceuticals
Takeda
Amgen
Biogen
UCB
Eli Lilly and Company
AstraZeneca
Antibody Therapeutics and Blood Antibody Therapeutics Segment by Type
IgG1
IgG4
Others
Antibody Therapeutics and Blood Antibody Therapeutics Segment by Application
Autoimmune
Tumor
Others
Antibody Therapeutics and Blood Antibody Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Therapeutics and Blood Antibody Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody Therapeutics and Blood Antibody Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Therapeutics and Blood Antibody Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Antibody Therapeutics and Blood Antibody Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- IgG1
- IgG4
- Others
Applications
- Autoimmune
- Tumor
- Others
Companies covered
- Roche
- Abbvie
- Johnson & Johnson
- Bristol-Myers Squibb
- Novartis
- Merck
- Alexion Pharmaceuticals
- Takeda
- Amgen
- Biogen
- UCB
- Eli Lilly and Company
- AstraZeneca
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2021-2032)
- 1.5.1 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size Growth Rate (2021-2032)
2 Antibody Therapeutics and Blood Antibody Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 IgG1
- 2.1.2 IgG4
- 2.1.3 Others
- 2.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Type
- 2.2.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Regions
- 2.3.1 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size Breakdown by Type (2021-2026)
3 Antibody Therapeutics and Blood Antibody Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Autoimmune
- 3.1.2 Tumor
- 3.1.3 Others
- 3.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Application
- 3.2.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Regions
- 3.3.1 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Antibody Therapeutics and Blood Antibody Therapeutics Industry Trends
- 4.2 Antibody Therapeutics and Blood Antibody Therapeutics Industry Drivers
- 4.3 Antibody Therapeutics and Blood Antibody Therapeutics Industry Opportunities and Challenges
- 4.4 Antibody Therapeutics and Blood Antibody Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Antibody Therapeutics and Blood Antibody Therapeutics Revenue (2021-2026)
- 5.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Antibody Therapeutics and Blood Antibody Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Antibody Therapeutics and Blood Antibody Therapeutics Company, Product Type & Application
- 5.5 Global Antibody Therapeutics and Blood Antibody Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Antibody Therapeutics and Blood Antibody Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Antibody Therapeutics and Blood Antibody Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Roche
- 6.1.1 Roche Company Information
- 6.1.2 Roche Business Overview
- 6.1.3 Roche Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Roche Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.1.5 Roche Recent Developments
- 6.2 Abbvie
- 6.2.1 Abbvie Company Information
- 6.2.2 Abbvie Business Overview
- 6.2.3 Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.2.5 Abbvie Recent Developments
- 6.3 Johnson & Johnson
- 6.3.1 Johnson & Johnson Company Information
- 6.3.2 Johnson & Johnson Business Overview
- 6.3.3 Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.3.5 Johnson & Johnson Recent Developments
- 6.4 Bristol-Myers Squibb
- 6.4.1 Bristol-Myers Squibb Company Information
- 6.4.2 Bristol-Myers Squibb Business Overview
- 6.4.3 Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.4.5 Bristol-Myers Squibb Recent Developments
- 6.5 Novartis
- 6.5.1 Novartis Company Information
- 6.5.2 Novartis Business Overview
- 6.5.3 Novartis Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Novartis Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.5.5 Novartis Recent Developments
- 6.6 Merck
- 6.6.1 Merck Company Information
- 6.6.2 Merck Business Overview
- 6.6.3 Merck Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Merck Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.6.5 Merck Recent Developments
- 6.7 Alexion Pharmaceuticals
- 6.7.1 Alexion Pharmaceuticals Company Information
- 6.7.2 Alexion Pharmaceuticals Business Overview
- 6.7.3 Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.7.5 Alexion Pharmaceuticals Recent Developments
- 6.8 Takeda
- 6.8.1 Takeda Company Information
- 6.8.2 Takeda Business Overview
- 6.8.3 Takeda Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Takeda Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.8.5 Takeda Recent Developments
- 6.9 Amgen
- 6.9.1 Amgen Company Information
- 6.9.2 Amgen Business Overview
- 6.9.3 Amgen Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Amgen Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.9.5 Amgen Recent Developments
- 6.10 Biogen
- 6.10.1 Biogen Company Information
- 6.10.2 Biogen Business Overview
- 6.10.3 Biogen Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Biogen Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.10.5 Biogen Recent Developments
- 6.11 UCB
- 6.11.1 UCB Company Information
- 6.11.2 UCB Business Overview
- 6.11.3 UCB Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 UCB Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.11.5 UCB Recent Developments
- 6.12 Eli Lilly and Company
- 6.12.1 Eli Lilly and Company Company Information
- 6.12.2 Eli Lilly and Company Business Overview
- 6.12.3 Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.12.5 Eli Lilly and Company Recent Developments
- 6.13 AstraZeneca
- 6.13.1 AstraZeneca Company Information
- 6.13.2 AstraZeneca Business Overview
- 6.13.3 AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 6.13.5 AstraZeneca Recent Developments
7 North America
- 7.1 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst